Galectin expression detected by 68Ga-galectracer PET as a predictive biomarker of radiotherapy resistance
Authors:
- 2 February 2022
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (8) , 2746-2760
Abstract
Purpose Hypoxia is a hallmark of solid tumors that is related to radiotherapy resistance. As galectin members, such as galectin-1 and galectin-3, are associated with tumor hypoxia, herein we aimed to investigate whether positron emission tomography (PET) imaging of galectin expression can be employed to effectively pinpoint tumor hypoxia, and to predict radiotherapy resistance. Methods We synthesized a galectin-targeting radiotracer, designated 68Ga-galectracer, by radiolabeling a thiodigalactoside derivative. The properties of 68Ga-galectracer for PET imaging of tumor hypoxia were characterized in three tumor hypoxia mouse models. Additionally, preliminary PET/CT was performed in two patients with lung cancer to investigate the potential application of 68Ga-galectracer for clinical imaging. Results High-contrast imaging was achieved in the murine acute hypoxia tumor model, A549 natural hypoxia model, and sorafenib treatment-induced hypoxic 4T1 tumor model by PET using 68Ga-galectracer. In fact, 68Ga-galectracer exhibited superior hypoxia detection to that of 18F-misonidazole in the 4T1 tumors. Moreover, tumors with high galectin expression levels, as detected by 68Ga-galectracer PET, exhibited significantly lower responses to subsequent radiotherapy compared to those with low galectin expression levels. In patients with lung cancer, PET imaging using 68Ga-galectracer provided data that were complementary to that of the glucose metabolic PET radiotracer 18F-fluorodeoxyglucose. Conclusion 68Ga-galectracer is a promising radiotracer for PET-based imaging of tumor hypoxia in vivo. Thus, hypoxia PET with 68Ga-galectracer could provide a noninvasive approach to proactively predict radiotherapy efficacy. Trial registration Chictr.org.cn (ChiCTR2000029522). Registered 03 February 2020.Keywords
Funding Information
- National Key R&D Program of China (2018YFE0205300)
- National Natural Science Foundation of China (81873907, 81920108020, 81871387)
- Beijing Natural Science Foundation (JQ19026, 7202027)
- Fundamental Research Funds for the Central Universities (BMU2021RCZX018, PKU2019LCXQ023)
This publication has 52 references indexed in Scilit:
- Ablation of Hypoxic Tumors with Dose-Equivalent Photothermal, but Not Photodynamic, Therapy Using a Nanostructured Porphyrin AssemblyACS Nano, 2013
- Imaging hypoxia to improve radiotherapy outcomeNature Reviews Clinical Oncology, 2012
- Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironmentCancer and Metastasis Reviews, 2012
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxiaProceedings of the National Academy of Sciences, 2012
- VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib TreatmentCancer Research, 2011
- Hypoxia and Hypoxia-Inducible Factors: Master Regulators of MetastasisClinical Cancer Research, 2010
- Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cellsCarcinogenesis, 2010
- Aerobic glycolysis in cancers: Implications for the usability of oxygen‐responsive genes and fluorodeoxyglucose‐PET as markers of tissue hypoxiaInternational Journal of Cancer, 2008
- Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer TherapeuticsChemotherapy, 2007
- Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune PrivilegeJournal of Clinical Oncology, 2005